SU5416 in Treating Patients With Refractory or Relapsed Multiple Myeloma

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2000
RATIONALE: SU5416 may stop the growth of multiple myeloma by stopping blood flow to the cancer cells. PURPOSE: Phase II trial to study the effectiveness of SU5416 in treating patients who have refractory or relapsed multiple myeloma.
Epistemonikos ID: c1ef9650189d092e1db4e2714a2a718702e132a0
First added on: May 03, 2024